MedTrace Logo

A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment

NCT01122563 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2011-01-13

No results posted yet for this study

Summary

This study is to evaluate change of overactive bladder symptom scores (OABSS) between, before and after solifenacin treatment to OAB subjects.

Conditions

Interventions

DRUG

Solifenacin

oral

Sponsors & Collaborators

  • Astellas Pharma Indonesia Inc.

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Indonesia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122563 on ClinicalTrials.gov